Exploring the intricate connection between genetics and cardiovascular health, cardiovascular pharmacogenomics stands at the forefront of medical innovation. This field delves into the genetic factors influencing how individuals respond to cardiovascular drugs, with a primary objective of fine-tuning treatment outcomes and mitigating potential adverse effects. Through a comprehensive analysis of genetic variations impacting drug metabolism, efficacy, and toxicity, cardiovascular pharmacogenomics endeavors to customize medication regimens based on each patient's distinct genetic profile. This personalized approach not only holds the potential to optimize the effectiveness of cardiovascular therapies but also aims to minimize the occurrence of side effects, thereby elevating overall patient outcomes. In an era of advancing genomic understanding, cardiovascular pharmacogenomics emerges as a pivotal player in the ongoing evolution toward precision medicine, paving the way for more nuanced and targeted treatments in the realm of cardiovascular diseases.
Title : New recommendations for the prevention of sudden cardiac death in athletes and recreational sports
Sekib Sokolovic, ASA Hospital Sarajevo, Bosnia and Herzegowina
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : An adult case of polysplenia syndrome associated with sinus node dysfunction
Apoorva Tripathi, Oxford University Hospitals, United Kingdom
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : A unique cell-driven phenomenon in the heart and the promising future of the innovative translational tools to manage cardiac self-renewal and regeneration
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Young hearts at risk: Hidden cardiovascular damage and the role of social determinants of health among youth with type 1 diabetes in Kenya
Phoebe Wamalwa, Ministry of Health, Kenya